Sino Competitors

Pink Sheets . USA . 
Stock . Sino Biopharmaceutical Limited
SBMFF Stock  USD 0.42  0.00  0.00%   
Sino Biopharmaceutical competes with Alpha Cognition, and Adagene; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Sino Biopharmaceutica competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Sino Biopharmaceutica to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Sino Biopharmaceutica Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Sino Biopharmaceutica competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.020.422.88
Details
Intrinsic
Valuation
LowRealHigh
0.020.352.81
Details
Naive
Forecast
LowNextHigh
0.010.412.87
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.400.450.49
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Sino Biopharmaceutica. Your research has to be compared to or analyzed against Sino Biopharmaceutica's peers to derive any actionable benefits. When done correctly, Sino Biopharmaceutica's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Sino Biopharmaceutical.

Sino Biopharmaceutica Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sino Biopharmaceutica and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Sino and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sino Biopharmaceutical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
PKTX
+ 0.35
ADAG
PKTX
+ 0.25
TSOI
ADAG
+ 0.25
ACOGF
PKTX
+ 0.24
ACOGF
MRZM
+ 0.23
ACOGF
VGLS
+ 0.19
ACOGF
  
High negative correlations   
PKTX
- 0.22
VGLS
ADAG
- 0.15
VGLS
MRZM
- 0.02
TSOI
PKTX
- 0.0
MYMX
MYMX
- 0.0
MRZM
MYMX
- 0.0
ADAG

Risk-Adjusted Indicators

There is a big difference between Sino Pink Sheet performing well and Sino Biopharmaceutica Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sino Biopharmaceutica's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Sino Biopharmaceutica Competitive Analysis

The better you understand Sino Biopharmaceutica competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sino Biopharmaceutica's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sino Biopharmaceutica's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SBMFF TSOI ACOGF VGLS ADAG MRZM MYMX PKTX
 0.00 
 0.42 
Sino
 16.67 
 0.0005 
Therapeutic
 0.75 
 6.62 
Alpha
 0.00 
 0.0001 
VGLS
 1.30 
 2.34 
Adagene
 25.00 
 0.05 
Marizyme
 0.00 
 0 
Mymetics
 9.88 
 0.01 
Protokinetix
Market Volatility
(90 Days Market Risk)
Abnormally volatile
Out of control
Risky
Out of control
Unstable
Out of control
Very steady
Out of control
Market Performance
(90 Days Performance)
Modest
Very Weak
Very Weak
Solid
Very Weak
OK
Very Weak
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
About Average
Below Average
Below Average
About Average
Below Average
Quite High
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Under Valued
Over Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Buy
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Hold
Cautious Hold
Hold
Strong Hold
Cautious Hold
Hold
Strong Hold
Current Ratio
1.55 X
0.36 X
3.08 X
0.01 X
3.10 X
1.74 X
0.01 X
0.54 X
Net Asset
60.54 B
1.72 M
12.88 M
1.32 M
115.73 M
66 M
7.63 M
446.23 K
Profit Margin
0.29 %
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
19.87 B
(2.33 M)
(18.93 M)
(3.43 M)
(14.95 M)
(10.83 M)
(1.96 M)
(2.33 M)
Operating Margin
0.16 %
(13.37) %
N/A
N/A
(45.35) %
(180.85) %
(1.76) %
N/A
Current Valuation
10.34 B
21.6 M
14.92 M
4.44 M
28.49 M
17.35 M
83.16 M
7.5 M
Price To Book
2.51 X
11.55 X
9.90 X
32.38 X
1.83 X
0.37 X
N/A
20.13 X
Current Asset
13.73 B
247 K
N/A
40 K
N/A
N/A
1.38 M
180 K
Five Year Return
0.74 %
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Retained Earnings
N/A
(3.21 M)
N/A
(109.84 M)
(277.75 M)
N/A
(81.98 M)
(28.25 M)
Beta
0.51
1.49
N/A
2.76
0.58
0.36
0.24
0.13
Number Of Employees
25.55 K
3
7
1
174
11
9
7
Shares Outstanding
18.81 B
2.61 B
61.02 M
107.88 M
44.27 M
10.13 M
303.76 M
316.85 M
Cash Flow From Operations
5.37 B
(718.92 K)
(9.88 M)
(1.91 M)
(28.45 M)
(5.79 M)
(1.7 M)
(889.89 K)
Annual Yield
0.03 %
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
5.21 B
15.53 K
1.14 M
3.38 M
22.31 M
495.32 K
162 K
N/A
Return On Equity
0.29
-12.27
-6.97
N/A
-0.46
-0.5
N/A
-4.03
Z Score
1.2
N/A
5.7
N/A
N/A
6.0
-1.4
N/A
Return On Asset
0.0451
-0.76
-1.61
-1.51
-0.2
-0.15
-0.14
-2.22
Book Value Per Share
1.64 X
0 X
0.03 X
(0.05) X
1.28 X
1.00 X
(0.21) X
0 X
Number Of Shares Shorted
N/A
N/A
N/A
N/A
1.51 K
N/A
N/A
N/A
Current Liabilities
7.73 B
489 K
N/A
5.46 M
N/A
N/A
51.24 M
40 K
Total Asset
60.54 B
1.72 M
12.88 M
1.32 M
115.73 M
66 M
7.63 M
446.23 K
Debt To Equity
0.31 %
0.50 %
0.27 %
N/A
0.15 %
0.07 %
N/A
31.50 %
Last Dividend Paid
0.083
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Target Price
N/A
N/A
2.75
0.15
10.54
N/A
N/A
N/A
Short Ratio
N/A
N/A
N/A
N/A
0.33 X
N/A
N/A
N/A
Shares Owned By Institutions
14.86 %
N/A
0.73 %
N/A
25.54 %
N/A
N/A
0.02 %
Market Capitalization
10.91 B
7.82 M
17.7 M
1.82 M
108.46 M
5.07 M
5.47 M
9.51 M
Price To Earning
24.17 X
(8.00) X
N/A
(0.14) X
N/A
N/A
(2.40) X
(9.86) X
Price To Earnings To Growth
0.53 X
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
0.41 X
81.80 X
N/A
N/A
126.72 X
133.06 X
12.17 X
N/A
Net Income
14.61 B
(2.96 M)
(19.55 M)
(6.19 M)
(18.95 M)
(11 M)
(4.73 M)
(2.33 M)
Earnings Per Share
0.06 X
(0) X
(0.17) X
(0.07) X
(0.72) X
(0.39) X
(0.02) X
(0.01) X
Shares Owned By Insiders
47.86 %
27.98 %
29.84 %
N/A
10.65 %
2.04 %
54.90 %
30.73 %
Revenue
26.86 B
145.96 K
N/A
N/A
18.11 M
210.28 K
3 K
N/A
Working Capital
6 B
(242 K)
N/A
(5.42 M)
81.99 M
N/A
(49.86 M)
140 K
Cash And Equivalents
15.67 B
197.29 K
5.98 M
22.92 K
168.04 M
2.04 M
350 K
18.83 K
Cash Per Share
0.85 X
N/A
0.10 X
N/A
3.87 X
0.05 X
N/A
N/A
Gross Profit
21.53 B
103.41 K
(37.5 K)
N/A
10.18 M
129.93 K
(545 K)
N/A
Day Typical Price
0.42
5.0E-4
6.67
1.0E-4
2.33
0.05
0.001
0.0089
Accumulation Distribution
N/A
0.17
0.0523
N/A
0.0171
N/A
N/A
N/A
Market Facilitation Index
N/A
1.0E-4
0.36
N/A
0.04
N/A
N/A
N/A
Daily Balance Of Power
0.0
(1.00)
(0.14)
9.2 T
0.75
9.2 T
0.0
9.2 T
Period Momentum Indicator
N/A
(0.0001)
(0.05)
N/A
0.03
0.01
N/A
8.0E-4
Rate Of Daily Change
1.0
0.83
0.99
9223372 T
1.01
1.25
1.0
1.1
Day Median Price
0.42
6.0E-4
6.7
1.0E-4
2.32
0.05
0.001
0.0089
Price Action Indicator
N/A
(0.0001)
(0.10)
1.0E-4
0.035
0.005
N/A
4.0E-4
Coefficient Of Variation
1346.71
38934.79
813.88
N/A
(5,534)
821.34
N/A
2407.24
Mean Deviation
0.7364
6.9
1976.96
N/A
4.38
9.89
N/A
9.39
Jensen Alpha
0.2825
(0.10)
1367.86
N/A
(0.15)
3.01
N/A
0.1874
Total Risk Alpha
(0.23)
(1.74)
(359.29)
N/A
(1.15)
(0.96)
N/A
(1.80)
Sortino Ratio
N/A
(0.01)
52.95
N/A
N/A
0.0726
N/A
0.0315
Downside Variance
N/A
195.48
357.89
N/A
N/A
1125.49
N/A
208.92
Standard Deviation
2.42
10.53
8154.0
N/A
6.14
21.13
N/A
14.28
Kurtosis
20.85
0.3505
66.0
N/A
2.13
9.65
N/A
2.62
Potential Upside
N/A
16.67
19.3
N/A
8.13
50.0
N/A
25.0
Treynor Ratio
(0.19)
0.018
(0.35)
N/A
(0.54)
(0.72)
N/A
0.188
Maximum Drawdown
23.8
50.79
66273.61
N/A
37.93
128.57
N/A
84.38
Variance
5.87
110.97
6.648769111E7
N/A
37.75
446.31
N/A
203.82
Market Risk Adjusted Performance
(0.18)
0.028
(0.34)
N/A
(0.53)
(0.71)
N/A
0.198
Risk Adjusted Performance
0.0636
0.0112
0.1039
N/A
(0.01)
0.1027
N/A
0.0412
Skewness
1.87
0.4903
8.12
N/A
(0.64)
2.42
N/A
0.4333
Semi Deviation
N/A
7.83
0.0
N/A
N/A
9.63
N/A
11.35
Information Ratio
0.0175
(0.01)
0.1229
N/A
(0.04)
0.1152
N/A
0.0319
Value At Risk
N/A
(14.29)
(16.18)
N/A
(9.52)
(20.00)
N/A
(18.71)
Expected Short fall
N/A
(16.28)
(2,460)
N/A
N/A
(56.94)
N/A
(14.06)
Downside Deviation
N/A
13.98
18.92
N/A
N/A
33.55
N/A
14.45
Semi Variance
N/A
61.3
(781.55)
N/A
N/A
92.76
N/A
128.73

Sino Biopharmaceutica Competition Performance Charts

Five steps to successful analysis of Sino Biopharmaceutica Competition

Sino Biopharmaceutica's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sino Biopharmaceutical in relation to its competition. Sino Biopharmaceutica's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Sino Biopharmaceutica in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sino Biopharmaceutica's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sino Biopharmaceutical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Sino Biopharmaceutica position

In addition to having Sino Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Manufacturing Thematic Idea Now

Manufacturing
Manufacturing Theme
Companies that provide goods across residential, commercial and industrial construction such as machinery, tools, or lumber production. The Manufacturing theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Manufacturing Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Sino Pink Sheet

Sino Biopharmaceutica financial ratios help investors to determine whether Sino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sino with respect to the benefits of owning Sino Biopharmaceutica security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY